What is the current valuation of the US neuropathology market in 2024?

The overall market valuation was $574.44 Million in 2024. Read More

What is the projected market size for the US neuropathology market by 2035?

The projected valuation for 2035 is $1263.9 Million. Read More

What is the expected CAGR for the US neuropathology market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 7.43%. Read More

What are the main segments of the US neuropathology market?

The main segments include Diagnostic Test, Application, and End-User. Read More

What is the valuation range for the biopsy segment in the Diagnostic Test category?

The biopsy segment is valued between $100.0 Million and $250.0 Million. Read More

How does the neurodegenerative diseases segment perform in terms of valuation?

The neurodegenerative diseases segment is valued between $150.0 Million and $350.0 Million. Read More

What is the market valuation for hospitals as an end-user in the US neuropathology market?

Hospitals are valued between $287.22 Million and $646.95 Million as an end-user. Read More

What is the valuation range for brain tumors in the Application segment?

The brain tumors segment is valued between $80.0 Million and $180.0 Million. Read More

What is the expected growth trend for the US neuropathology market in the coming years?

The market appears to be on a growth trajectory, with a projected valuation increase to $1263.9 Million by 2035. Read More

US Neuropathology Market

Q: Which companies are the key players in the US neuropathology market?

Key players include Roche, Thermo Fisher Scientific, Abbott Laboratories, Siemens Healthineers, Philips, GE Healthcare, Bristol-Myers Squibb, Merck KGaA, and Agilent Technologies. Read More

ID: MRFR/Pharma/18440-HCR 100 Pages Satyendra Maurya Last Updated: September 10, 2026

US Neuropathology Market Research Report By Diagnostic Test (Biopsy, Body fluids, Peripheral blood smears, Tissue resections, Others), By Application (Cerebral hypoxia and stroke, Perinatal disorders, CNS infections, Demyelinative diseases, Brain tumors, Neurodegenerative diseases, Inherited metabolic disorders, Peripheral neuropathy, Myopathology) and By End User (Hospitals, Clinics, Research centers, Others) - Growth & Industry Forecast 2025 To 2035

US Neuropathology Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.43%

2024 Market Size$ 574.44 Million

2025 Market Size$ 617.13 Million

2035 Market Size$ 1,263.9 Million

Key Players

Roche

Thermo Fisher Scientific

Abbott Laboratories

Siemens Healthineers

Philips

GE Healthcare

Trends

Technological Advancements in Diagnostics
Increased Focus on Personalized Medicine
Rising Investment in Research and Development

Opportunities

Advancements in Biomarker Discovery
Increased Funding for Neurological Research
Growing Prevalence of Neurological Disorders

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Diagnostic Test (USD Million)
  1. 4.1.1 biopsy
  2. 4.1.2 body fluids
  3. 4.1.3 peripheral blood smears
  4. 4.1.4 tissue resections
  5. 4.1.5 others
2. 4.2 Construction, BY Application (USD Million)
  1. 4.2.1 cerebral hypoxia and stroke
  2. 4.2.2 perinatal disorders
  3. 4.2.3 CNS infections
  4. 4.2.4 demyelinative diseases
  5. 4.2.5 brain tumors
  6. 4.2.6 neurodegenerative diseases
  7. 4.2.7 inherited metabolic disorders
  8. 4.2.8 peripheral neuropathy
  9. 4.2.9 myopathology
3. 4.3 Construction, BY End-User (USD Million)
  1. 4.3.1 hospitals
  2. 4.3.2 clinics
  3. 4.3.3 research centers
  4. 4.3.4 others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Thermo Fisher Scientific (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Abbott Laboratories (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Siemens Healthineers (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Philips (NL)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 GE Healthcare (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck KGaA (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Agilent Technologies (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DIAGNOSTIC TEST
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF CONSTRUCTION
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CONSTRUCTION
8. 6.8 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 SUPPLY / VALUE CHAIN: CONSTRUCTION
11. 6.11 CONSTRUCTION, BY DIAGNOSTIC TEST, 2024 (% SHARE)
12. 6.12 CONSTRUCTION, BY DIAGNOSTIC TEST, 2024 TO 2035 (USD Million)
13. 6.13 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
14. 6.14 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Million)
15. 6.15 CONSTRUCTION, BY END-USER, 2024 (% SHARE)
16. 6.16 CONSTRUCTION, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSTIC TEST, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

US Neuropathology Market Segmentation

US Neuropathology Market By Diagnostic Test (USD Million, 2025-2035)

biopsy
body fluids
peripheral blood smears
tissue resections
others

US Neuropathology Market By Application (USD Million, 2025-2035)

cerebral hypoxia and stroke
perinatal disorders
CNS infections
demyelinative diseases
brain tumors
neurodegenerative diseases
inherited metabolic disorders
peripheral neuropathy
myopathology

US Neuropathology Market By End-User (USD Million, 2025-2035)

hospitals
clinics
research centers
others

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”